{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:53:57Z","timestamp":1787025237036,"version":"build-2736575974"},"reference-count":61,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: This study aimed to evaluate the efficacy and safety of argon\u2013helium cryoablation combined with Programmed Death-1 (PD-1) inhibitors versus PD-1 inhibitors plus chemotherapy in treating non-small cell lung cancer (NSCLC).\nPatient\/material and methods: In this single-center, open-label, randomized controlled trial, 60 NSCLC patients treated between December 2020 and December 2023 were enrolled. Patients were randomly assigned (1:1) to either a study group (argon\u2013helium cryoablation + PD-1 inhibitor, n = 30) or a control group (PD-1 inhibitor + chemotherapy, n = 30). Allocation was concealed using sequentially numbered, opaque, sealed envelopes (SNOSE). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included short-term efficacy \u2013 objective response rate (ORR), disease control rate (DCR) \u2013 immune function changes (CD4+, CD8+, CD4+\/CD8+), and adverse reactions, assessed after four cycles and during a 1-year follow-up.\nResults: ORR and DCR were higher in the study group (ORR: 73.33% vs. 53.33%; DCR: 90.00% vs. 83.33%), though not statistically significant (P &gt; 0.05). Baseline immune parameters were similar. After four cycles, the study group showed statistically significantly higher CD4+ and CD4+\/CD8+ ratios, and lower CD8+ levels (all P &lt; 0.001). Adverse reactions were comparable between groups (P &gt; 0.05). At 1-year follow-up, the PFS rate was 63.3% vs. 43.3%. The study group had a statistically significantly better OS (median not reached vs. 10.3 months, P = 0.003) and longer median PFS (9.6 vs. 8.3 months, P = 0.005).\nInterpretation: Argon\u2013helium cryoablation combined with PD-1 inhibitors statistically significantly improved OS, PFS and immune function in NSCLC patients, offering a promising alternative to standard therapy.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.44215","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:09:35Z","timestamp":1763017775000},"page":"1523-1530","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of argon\u2013helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer"],"prefix":"10.2340","volume":"64","author":[{"given":"Zheng","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"132722","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","DOI":"10.3322\/caac.21763"},{"key":"132723","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"132724","doi-asserted-by":"crossref","unstructured":"Yang H, Liu Y, Chen L, Zhao J, Guo M, Zhao X, et al. miRNA-based therapies for lung cancer: opportunities and challenges? Biomolecules. 2023;13(6):877.","DOI":"10.3390\/biom13060877"},{"key":"132725","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/biom13060877","DOI":"10.3390\/biom13060877"},{"key":"132726","doi-asserted-by":"crossref","unstructured":"Berg CD, Schiller JH, Boffetta P, Cai J, Connolly C, Kerpel-Fronius A, et al. Air pollution and lung cancer: a review by international association for the study of lung cancer early detection and screening committee. J Thorac Oncol. 2023;18(10):1277\u201389.","DOI":"10.1016\/j.jtho.2023.05.024"},{"key":"132727","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jtho.2023.05.024","DOI":"10.1016\/j.jtho.2023.05.024"},{"key":"132728","unstructured":"Roelofsz D, Rampon G. Lung cancer in Missouri. MO Med. 2024;121(5):368\u201372."},{"key":"132729","doi-asserted-by":"crossref","unstructured":"Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H. Traditional Chinese medicine in lung cancer treatment. Mol Cancer. 2025;24(1):57.","DOI":"10.1186\/s12943-025-02245-6"},{"key":"132730","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12943-025-02245-6","DOI":"10.1186\/s12943-025-02245-6"},{"key":"132731","doi-asserted-by":"crossref","unstructured":"Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(4):643\u201352.","DOI":"10.1016\/j.jtho.2020.11.026"},{"key":"132732","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jtho.2020.11.026","DOI":"10.1016\/j.jtho.2020.11.026"},{"key":"132733","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer. Version 3.2024. Published March 15, 2024. [Accessed December 12, 2024] Available from https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."},{"key":"132734","doi-asserted-by":"crossref","unstructured":"Lv Y, Jin Y, Yan Q, Yuan D, Wang Y, Li X, et al. The value of 64-slice spiral CT perfusion imaging in the treatment of liver cancer with argon-helium cryoablation. Oncol Lett. 2016;12(6):4584\u20138.","DOI":"10.3892\/ol.2016.5241"},{"key":"132735","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3892\/ol.2016.5241","DOI":"10.3892\/ol.2016.5241"},{"key":"132736","doi-asserted-by":"crossref","unstructured":"Campbell WA, Makary MS. Advances in image-guided ablation therapies for solid tumors. Cancers. 2024;16(14):2560.","DOI":"10.3390\/cancers16142560"},{"key":"132737","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers16142560","DOI":"10.3390\/cancers16142560"},{"key":"132738","doi-asserted-by":"crossref","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (New York, NY). 2018;359(6382):1350\u20135.","DOI":"10.1126\/science.aar4060"},{"key":"132739","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.aar4060","DOI":"10.1126\/science.aar4060"},{"key":"132740","doi-asserted-by":"crossref","unstructured":"Kim Y, Kim G, Kim S, Cho B, Kim SY, Do EJ, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. 2024;32(8):1380\u201393.e9.","DOI":"10.1016\/j.chom.2024.06.010"},{"key":"132741","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.chom.2024.06.010","DOI":"10.1016\/j.chom.2024.06.010"},{"key":"132742","doi-asserted-by":"crossref","unstructured":"Yu D, Yang P, Lu X, Huang S, Liu L, Fan X. Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer. Cell Commun Signal. 2023;21(1):169.","DOI":"10.1186\/s12964-023-01184-3"},{"key":"132743","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12964-023-01184-3","DOI":"10.1186\/s12964-023-01184-3"},{"key":"132744","doi-asserted-by":"crossref","unstructured":"Ma F, Qi Z, Liao G, Zhao L, Su X, Dong C, et al. Study on PD-1 inhibitor combined with recombinant human endostatin and chemotherapy followed by IMRT in the treatment of advanced NSCLC. Medicine. 2025;104(6):e41306.","DOI":"10.1097\/MD.0000000000041306"},{"key":"132745","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MD.0000000000041306","DOI":"10.1097\/MD.0000000000041306"},{"key":"132746","unstructured":"Yakkala C, Vaughan D, Kuchi N, Al Tabaa Y, Siah SBB, Hayes C, et al. Cryoablation and immunotherapy: an attractive combination for cancer treatment. J ImmunoTher Cancer. 2019;7(1):337."},{"key":"132747","doi-asserted-by":"crossref","unstructured":"Liu SY, Chen Q, Zhou C, Zhang H, Li W, Chen J, et al. Neoadjuvant camrelizumab for non-small cell lung cancer: a retrospective multicenter, real-world study (CTONG2004). Cancer Immunol Immunother. 2023;72(7):2257\u201365.","DOI":"10.1007\/s00262-023-03412-8"},{"key":"132748","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00262-023-03412-8","DOI":"10.1007\/s00262-023-03412-8"},{"key":"132749","doi-asserted-by":"crossref","unstructured":"Feng J, Guiyu D, Xiongwen W. The clinical efficacy of argon-helium knife cryoablation combined with nivolumab in the treatment of advanced non-small cell lung cancer. Cryobiology. 2021;102:92\u20136.","DOI":"10.1016\/j.cryobiol.2021.07.007"},{"key":"132750","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cryobiol.2021.07.007","DOI":"10.1016\/j.cryobiol.2021.07.007"},{"key":"132751","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed). 2010;340:c332.","DOI":"10.1136\/bmj.c332"},{"key":"132752","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.c332","DOI":"10.1136\/bmj.c332"},{"key":"132753","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990). 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"132754","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"132755","doi-asserted-by":"crossref","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. J ImmunoTher Cancer. 2024;12(11):e009240.","DOI":"10.1136\/jitc-2024-009240"},{"key":"132756","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/jitc-2024-009240","DOI":"10.1136\/jitc-2024-009240"},{"key":"132757","doi-asserted-by":"crossref","unstructured":"Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST). Ups J Med Sci. 2013;118(1):16\u201322.","DOI":"10.3109\/03009734.2012.729104"},{"key":"132758","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/03009734.2012.729104","DOI":"10.3109\/03009734.2012.729104"},{"key":"132759","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published November 27, 2017. [Accessed December 15, 2024] Available from https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctcae.htm."},{"key":"132760","doi-asserted-by":"crossref","unstructured":"Garassino MC, Gadgeel S. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992\u20138.","DOI":"10.1200\/JCO.22.01989"},{"key":"132761","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.22.01989","DOI":"10.1200\/JCO.22.01989"},{"key":"132762","doi-asserted-by":"crossref","unstructured":"Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, et al. Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC. J Thorac Oncol. 2023;18(11):1524\u201337.","DOI":"10.1016\/j.jtho.2023.05.019"},{"key":"132763","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jtho.2023.05.019","DOI":"10.1016\/j.jtho.2023.05.019"},{"key":"132764","unstructured":"Hu J, Yuan X, Zhang Y. Efficacy of different ablation methods combined with targeted therapy for non-small cell lung cancer and their effects on serum indexes in patients. Shaanxi Med J. 2024;53(04):527\u201330."},{"key":"132765","doi-asserted-by":"crossref","unstructured":"Niu LZ, Li JL, Zeng JY. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol. 2013;19(22):3473\u201380.","DOI":"10.3748\/wjg.v19.i22.3473"},{"key":"132766","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3748\/wjg.v19.i22.3473","DOI":"10.3748\/wjg.v19.i22.3473"},{"key":"132767","unstructured":"Li Y, Feng H, Nie Z. Long-term efficacy and risk factor analysis of percutaneous argon-helium cryoablation for advanced non-small cell lung cancer. J Clin Oncol. 2010;15(4):346\u20139."},{"key":"132768","doi-asserted-by":"crossref","unstructured":"Johnson AM, Boland JM, Wrobel J, Klezcko EK, Weiser-Evans M, Hopp K, et al. Cancer cell-specific major histocompatibility complex II expression as a determinant of the immune infiltrate organization and function in the NSCLC tumor microenvironment. J Thorac Oncol. 2021;16(10):1694\u2013704.","DOI":"10.1016\/j.jtho.2021.05.004"},{"key":"132769","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jtho.2021.05.004","DOI":"10.1016\/j.jtho.2021.05.004"},{"key":"132770","doi-asserted-by":"crossref","unstructured":"Wang XR, Jiang ZB, Xu C, Meng WY, Liu P, Zhang YZ, et al. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacol Res. 2022;179:106198.","DOI":"10.1016\/j.phrs.2022.106198"},{"key":"132771","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106198","DOI":"10.1016\/j.phrs.2022.106198"},{"key":"132772","doi-asserted-by":"crossref","unstructured":"Shi L, Lu J, Zhong D, Song M, Liu J, You W, et al. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy. J ImmunoTher Cancer. 2023;11(1):e005902.","DOI":"10.1136\/jitc-2022-005902"},{"key":"132773","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/jitc-2022-005902","DOI":"10.1136\/jitc-2022-005902"},{"key":"132774","doi-asserted-by":"crossref","unstructured":"Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60\u20135.","DOI":"10.1038\/nature22079"},{"key":"132775","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nature22079","DOI":"10.1038\/nature22079"},{"key":"132776","doi-asserted-by":"crossref","unstructured":"Zhu X, Sun L, Song N, He W, Xie B, Hu J, et al. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate002): an open-label, single-arm, phase 2 trial. BMC Med. 2022;20(1):493.","DOI":"10.1186\/s12916-022-02696-4"},{"key":"132777","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12916-022-02696-4","DOI":"10.1186\/s12916-022-02696-4"},{"key":"132778","unstructured":"Zhang Y, Zhu T, Wang Q, Wang J, Chen X. Effects of PD-1 inhibitor combined with anti-angiogenic drugs on efficacy and immune function of non-small cell lung cancer. Am J Transl Res. 2022;14(11):8225\u201333."},{"key":"132779","unstructured":"Li L, Liu C, Cao S. Clinical significance and impact on immune function of cryoablation in lung cancer patients. Chin J Cancer Prev Treat. 2021;28(16):1231\u20135."},{"key":"132780","doi-asserted-by":"crossref","unstructured":"Yin C, Zou GR, He Y, Li J, Yan HW, Su Z, et al. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2023;15(4):1838\u201347.","DOI":"10.21037\/jtd-23-387"},{"key":"132781","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.21037\/jtd-23-387","DOI":"10.21037\/jtd-23-387"},{"key":"132782","unstructured":"Chen J, Deng A, Li X. Effect of argon-helium knife cryoablation combined with TP chemotherapy regimen on serum tumor marker levels and prognosis in lung cancer. Chin Med Equip. 2020;17(09):94\u20138."}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44215\/52014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44215\/52014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:23Z","timestamp":1763017823000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/44215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":61,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.44215","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}